VSTM Quote, Financials, Valuation and Earnings

Merck & has a net margin of -82.56% compared to Verastem's net margin of 32.71%. Verastem's return on equity of -120.71% beat Merck &'s return on equity of 39.02%.

Verastem has a consensus price target of $15.75, signalling upside risk potential of 111.13%. On the other hand Merck & has an analysts' consensus of $102.71 which suggests that it could grow by 39.8%. Given that Verastem has higher upside potential than Merck &, analysts believe Verastem is more attractive than Merck &.

Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.3% to investors and pays a quarterly dividend of $0.81 per share. Verastem pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Verastem quarterly revenues are $10M, which are smaller than Merck & quarterly revenues of $15.5B. Verastem's net income of -$64.6M is lower than Merck &'s net income of $5.1B. Notably, Verastem's price-to-earnings ratio is -- while Merck &'s PE ratio is 10.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 2.92x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -82.56% compared to Verastem's net margin of -49.65%. Verastem's return on equity of -120.71% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Verastem has a consensus price target of $15.75, signalling upside risk potential of 111.13%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 42.86%. Given that Verastem has higher upside potential than NovaBay Pharmaceuticals, analysts believe Verastem is more attractive than NovaBay Pharmaceuticals.

Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Verastem's net income of -$64.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Verastem's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Oragenics's return on equity of --.

Verastem has a consensus price target of $15.75, signalling upside risk potential of 111.13%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 410.73%. Given that Oragenics has higher upside potential than Verastem, analysts believe Oragenics is more attractive than Verastem.

Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Oragenics quarterly revenues of --. Verastem's net income of -$64.6M is lower than Oragenics's net income of -$3.3M. Notably, Verastem's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 1.22x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -82.56% compared to Verastem's net margin of --. Verastem's return on equity of -120.71% beat Theriva Biologics's return on equity of --.

Verastem has a consensus price target of $15.75, signalling upside risk potential of 111.13%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1134.13%. Given that Theriva Biologics has higher upside potential than Verastem, analysts believe Theriva Biologics is more attractive than Verastem.

Verastem has a beta of 0.855, which suggesting that the stock is 14.503% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Verastem has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Verastem quarterly revenues are $10M, which are larger than Theriva Biologics quarterly revenues of --. Verastem's net income of -$64.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, Verastem's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.